NCT01646398 - A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older | Biotech Hunter

Enrollment

764

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions

Pneumococcal VaccinesPneumococcal Conjugate Vaccine

Interventions

BIOLOGICAL

13-valent pneumococcal conjugate vaccine

A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.

BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.

Trial Locations (8)

Medical Co.LTA PS Clinic, Fukuoka

Seishinkai Inoue Hospital, Itoshima

Yokohama Minoru Clinic, Yokohama

Uzumasa Medical Clinic, Kyoto

Senbon Hospital, Osaka

Oda Clinic, Shinjuku-ku

Sone Clinic, Shinjuku-ku

Medical Co. LTA Sumida Hospital, Sumida-ku